German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Several Houston institutions scored funding from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

From Your Site Articles
MD Anderson Cancer Center received $3 million to establish a new genomics research hub. Photo by F. Carter Smith/Courtesy of MD Anderson

Houston hospital to establish genomics research hub as part of CPRIT's $60M round of grants

coming soon

Houston’s University of Texas MD Anderson Cancer Center will create a genomics research hub thanks to a nearly $3 million award from the Cancer Prevention and Research Institute of Texas, or CPRIT.

“This groundbreaking facility will have a profound impact on cancer research, and improving the diagnosis and treatment of cancer patients in Texas,” says CPRIT.

CPRIT gave the monetary award to Nicholas Navin, a professor at MD Anderson and at the biomedical sciences school within the University of Texas Health Science Center at Houston (UTHealth Houston).

The new facility will specialize in advanced spatial genomics, which creates a three-dimensional “atlas” that’s been dubbed “the Google Map of the human body,” according to CPRIT.

“Spatial genomics is an exciting new field that allows cancer researchers to directly connect the images of cells and their tissue structures with genomic data while preserving the spatial context,” CPRIT explains. “This provides the researchers with the ability to see exactly where distinct types of cells are located within a tumor, and determine the genes and proteins they are expressing.”

Until recently, most genomic technologies such as DNA and RNA sequencing required scientists to “grind up” tumor tissues to extract molecules for analysis, according to CPRIT.

“This process means losing the complex composition of the different cell types and their spatial arrangement within the tumor, which makes it difficult to understand the complex environment of cancer cells,” the institute adds.

MD Anderson’s new genomics hub will feature tissue processing, slide imaging, spatial genomics technologies, and spatial data analysis methods for cancer researchers within the Texas Medical Center and around the state.

In other CPRIT funding news, three local medical institutions received a total of $8 million for recruitment of four cancer researchers.

MD Anderson received half of the $8 million from CPRIT. The money will go toward bring aboard:

  • Hojong Yoon. Yoon, recipient of a $2 million scholar recruitment award, is a postdoctoral student at the Cambridge, Massachusetts-based Broad Institute. The institute, affiliated with Harvard University and MIT, is a research organization. Yoon’s research focuses on targeted cancer therapy.
  • Marianna Trakala. Trakala, recipient of a $2 million scholar recruitment award, is a postdoctoral researcher at MIT’s Koch Institute for Integrative Cancer Research. She is studying how small conditional RNA (scRNA) causes a response that triggers activation of the immune system and elimination of cancer cells from tissue.

The Baylor College of Medicine and the University of Texas Health Science Center at Houston (UTHealth Houston) each received one $2 million scholar recruitment award:

  • Louai Labanieh, a postdoctoral researcher at Stanford University’s Parker Institute for Cancer Immunotherapy, is joining the Baylor College of Medicine. Labanieh’s research involves engineering next-generation cells to improve cancer immunotherapy.
  • Yanjun Sun, a neuroscientist who is a postdoctoral scholar at Stanford, is joining UTHealth Houston.

In all, CPRIT recently doled out more than $60 million for cancer-fighting efforts around the state. Aside from the Baylor College of Medicine, MD Anderson, and UTHealth Houston, Rice University and Texas Southern University received CPRIT funding.

“By supporting the vital core facilities that researchers need, funding groundbreaking research, and deepening the bench of clinical trial investigators, CPRIT is fulfilling the promise central to our mission: We are helping Texans conquer cancer,” says Kristen Doyle, CEO of CPRIT.

The grants, which are between $2 million to $6 million each, are earmarked for recruitment of prominent researchers. Photo via Getty Images

Houston health care institutions receive $22M to attract top recruits

coming to Hou

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14.

Milner, an expert in photomedicine for surgery and diagnostics, is a professor of surgery and biomedical engineering at the Beckman Laser Institute & Medical Clinic at the University of California, Irvine and the university’s Chao Family Comprehensive Cancer Center

In 2013, Milner was named Inventor of the Year by the University of Texas at Austin. At the time, he was a professor of biomedical engineering at UT. One of his major achievements is co-development of the MasSpec Pen, a handheld device that identifies cancerous tissue within 10 seconds during surgical procedures.

Skoda is a professor of molecular medicine in the Department of Biomedicine at the University of Basel and the University Hospital Basel, both in Switzerland. He specializes in developing treatments for myeloproliferative neoplasms, which are a group of blood diseases including leukemia.

Other recruitment grants provided by the institute to Houston-area organizations are:

  • $4 million for recruitment of Susan Bullman to the University of Texas M.D. Anderson Cancer Center. She was an assistant professor at Seattle’s Fred Hutchinson Cancer Center, where she studied the connection between microbes and cancer.
  • $4 million for recruitment of Oren Rom to the University of Texas M.D. Anderson Cancer Center. Rom is an assistant professor of pathology and translational pathobiology at Louisiana State University Shreveport.
  • Nearly $2 million for recruitment of Lauren Hagler to conduct RNA cancer biology at Texas A&M University. She is a postdoctoral scholar in biochemistry at Stanford University.

The institute also awarded grants to five companies in the Houston area:

  • $4.7 million to 7 Hills Pharma for development of immunotherapies to treat cancer and prevent infectious diseases.
  • $4.5 million to Indapta Therapeutics for the Phase 1 trial of a cell therapy for treatment of multiple myeloma and non-Hodgkin’s lymphoma.
  • $2.75 million to Bectas Therapeutics for development of antibodies and biomarkers to overcome a type of resistance T-cell checkpoint therapy.
  • $2.69 million to MS Pen Technologies for development of technology that differentiates between normal tissue and cancerous tissue during surgery.
  • $2.58 million to Crossbridge Bio for development of an antibody-drug combination to treat certain solid tumors.
The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia, one of the most common childhood cancers. Photo via Getty Images

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

Several Houston organizations have received millions from the Cancer Prevention and Research Institute of Texas. Photo via tmc.edu

Texas organization grants $68.5M to Houston institutions for recruitment, research

cha-ching

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.”

He also is co-founder and former CEO of Xilis, a Durham, North Carolina-based oncology therapy startup that raised $70 million in series A funding in 2021. Before joining the institute in 2021, the Stanford University graduate was an associate professor at Duke University in Durham.

Shen and Xilis aren’t strangers to MD Anderson.

In 2023, MD Anderson said it planned to use Xilis’ propriety MicroOrganoSphere (MOS) technology for development of novel cancer therapies.

“Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current … models, which we hope will bring medicines to patients more quickly,” Shen said in an MD Anderson news release.

Here are the two other Cancer Prevention and Research Institute of Texas (CPRIT) awards that will bring noted cancer researchers to Houston:

  • $4 million to attract David Sarlah to Rice University from the University of Illinois, where he is an associate professor of chemistry. Sarlah’s work includes applying the principles of chemistry to creation of new cancer therapies.
  • $2 million to lure Vishnu Dileep to the Baylor College of Medicine from the Massachusetts Institute of Technology (MIT), where he is a postdoctoral fellow. His work includes the study of cancer genomes.

CPRIT also handed out more than $56.5 million in grants and awards to seven institutions in the Houston area. Here’s the rundown:

  • MD Anderson Cancer Center — Nearly $25.6 million
  • Baylor College of Medicine — Nearly $11.5 million
  • University of Texas Health Science Center at Houston — More than $6 million
  • Rice University — $4 million
  • University of Texas Medical Branch at Galveston — More than $3.5 million
  • Methodist Hospital Research Institute — More than $3.3 million
  • University of Houston — $1.4 million

Dr. Pavan Reddy, a CPRIT scholar who is a professor at the Baylor College of Medicine and director of its Dan L Duncan Comprehensive Cancer Care Center, says the CPRIT funding “will help our investigators take chances and explore bold ideas to make innovative discoveries.”

The Houston-area funding was part of nearly $99 million in grants and awards that CPRIT recently approved.

Here's what Houston organizations are benefitting from the latest CPRIT funding announcement. Photo via Getty Images

Houston organizations snag chunk of recently announced $49M cancer research grant funding

show me the money

Houston’s Baylor College of Medicine is beefing up its team of cancer researchers.

The college just received $6 million from the state agency Cancer Prevention and Research Institute of Texas (CPRIT) to recruit three cancer researchers: Graham Erwin, Michael Robertson and Dr. Varun Venkataramani. Each researcher is getting $2 million.

In addition, the University of Texas MD Anderson Cancer Center snagged a $2 million CPRIT grant to recruit Simon Eschweiler.

In all, CPRIT recently announced $49 million in cancer research and prevention grants, including nearly $24 million for recruitment of cancer researchers.

Here’s a rundown of the recruitment grants awarded in Houston:

  • Graham Erwin. Erwin is a postdoctoral fellow at Stanford University’s Stanford Cancer Institute. He’s a biologist who specializes in DNA sequencing related to the development of cancer therapeutics and diagnostics.
  • Michael Robertson. Robertson also is a postdoctoral fellow at Stanford. He focuses on molecular and cellular physiology at Stanford’s medical school.
  • Dr. Varun Venkataramani. Venkataramani, a neuroscientist, is a brain tumor researcher at University Hospital Heidelberg, one of the largest hospitals in Germany.
  • Simon Eschweiler. Eschweiler is a research assistant professor at Southern California’s La Jolla Institute for Immunology. He specializes in immunotherapy for cancer patients.

Aside from the recruitment grants, three institutions in the Houston area received nearly $6 million in funding for cancer treatment and prevention programs. Here’s an overview of those grants:

  • Almost $2.5 million for expansion of a program at the University of Texas Medical Branch at Galveston that supplies HPV vaccinations for new mothers.
  • Nearly $2.5 million for an MD Anderson program that promotes physical activity for cancer survivors.
  • Almost $500,000 for an MD Anderson program to increase treatment of tobacco users who are participating in opioid treatment programs.
  • Nearly $500,000 for a University of Houston program designed to help LGBTQ+ Texans lead tobacco-free lives.

“From new research programs, recruitment of preeminent scientists to Texas, pilot studies, new technology, and expanding the reach of successful cancer prevention programs, [the] grants highlight the effect CPRIT is having on not just cancer research and prevention efforts, but on life science infrastructure in Texas,” Wayne Roberts, the organization’s CEO, said in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston innovators join prestigious group of inventors as senior members

top honor

Houston is home to four new senior members of the National Academy of Inventors.

To be eligible to be an NAI Senior Member, candidates must be active faculty, scientists and administrators from NAI member institutions that have demonstrated innovation and produced technologies that have “brought, or aspire to bring, real impact on the welfare of society,” according to the NAI. The members have also succeeded in patents, licensing and commercialization, and educating and mentoring.

The University of Houston announced that three professors were selected to join the prestigious NAI list of senior members. UH now has 39 faculty members on the NAI list.

“We congratulate these three esteemed colleagues on being named NAI Senior Members,” Ramanan Krishnamoorti, vice president for energy and innovation at UH, said in a news release. “This recognition is a testament to their dedication, research excellence and pursuit of real-world impact by knowledge and technologies. Their achievements continue to elevate the University as a leader in innovation and entrepreneurship.”

UH’s new senior members include:

  • Birol Dindoruk, the American Association of Drilling Engineers Endowed Professor of Petroleum Engineering and Chemical and Biomolecular Engineering at the Cullen College of Engineering. He is known for his research in carbon capture and storage, fluid-rock interactions and hydrogen storage. He holds three patents.
  • Megan Robertson, the Neal R. Amundson professor of chemical and biomolecular engineering at UH’s Cullen College of Engineering. She is developing new polymers and groundbreaking strategies for recycling and reusing plastics. Robertson currently has three patents and two more patent applications pending.
  • Francisco Robles Hernandez, a professor of mechanical engineering technology at the UH College of Technology. He holds four patents, and several others are under review. His work focuses on carbon materials, including pioneering work with graphene and designs with steel and aluminum used in automotives and railroads.

“As an inventor, this is one of the highest honors you can be awarded, so I am very proud to receive it,” Robles Hernandez said in a news release. “UH has been instrumental in supporting my research and innovation efforts, but it’s the creativity of the students here that makes it successful.”

Allison Post, associate director of electrophysiology research and innovations and manager of innovation partnerships at the Texas Heart Institute at Baylor College of Medicine, also made the list.

Post was recognized for her work in biomedical engineering and commitment to advancing cardiovascular care through innovations. Post is the youngest member to be inducted this year.

Other notable Texas honorees include Emma Fan from the University of Texas, Arum Han from Texas A&M and Panos Shiakolas at UT Arlington.

In 2024, Edward Ratner, a computer information systems lecturer in the Department of Information Science Technology at the University of Houston’s Cullen College of Engineering, and Omid Veiseh, a bioengineer at Rice University and director of the Biotech Launch Pad, were named NAI fellows.

The Senior Member Induction Ceremony will honor the 2025 class at NAI’s Annual Conference June 23-26 in Atlanta, Georgia.

Plans revealed for $2 billion expansion of Houston convention district

coming soon

Mayor John Whitmire and Houston First Corporation shared a new master plan for the George R. Brown Convention Center and its surrounding area last week. The plan features expanded exhibition space, a living roof, a pedestrian plaza with access to Toyota Center and more.

The project will be funded by the state’s portion of incremental Hotel Occupancy Tax revenue growth within a three-mile radius of the GRB for 30 years, which is estimated to total about $2 billion, according to a release from Houston First.

The first phase of the project, which is slated to be completed by 2028, will focus on developing a 700,000-square-foot convention facility known as GRB South.

GRB South will feature:

  • Two exhibition halls, totaling 150,000 square feet
  • A 50,000-square-foot multipurpose hall that opens to the new Central Plaza
  • The 100,000-square-foot Central Plaza, an extension of the Avenida Plaza that will connect to Discovery Green and Toyota Center
  • Atrium flex hall totaling 25,000 square feet
  • 225,000 square feet of contiguous exhibit space
  • A 60,000-80,000-square-foot ballroom
  • Ground-level spaces for retail and restaurants
  • A central atrium, providing each level with natural light

The design of the space is inspired by the Houston area's native prairies and will use low-carbon materials, high-efficiency building systems with rainwater collection and water-reduction strategies. A living roof on top of the GRB South will also have the potential for solar integration.

"It is imperative for us to stay competitive and meet the needs of our meetings and convention customers,” Michael Heckman, president and CEO of Houston First, said in the release. “This project will not only accomplish that but will establish a gathering space that will be the epicenter for entertainment, sports, and city-wide events, accentuating our ability to capitalize on Houston's unique offerings.”

The full campus renovation is expected to wrap in 2038, and construction will be managed in phases. Houston First reports that construction should not impact events currently scheduled as GRB.

“This project is truly transformative for downtown Houston, a lasting legacy that will solidify our position as a top-tier convention and entertainment destination,” Mayor John Whitmire said in the release. “Most importantly, we are creating a space that will build community, foster connection, and shape the future of Houston.”

Explore renderings of the plans below.

  

Rendering courtesy Houston First.

Tech company floats plan for futuristic shipyard on Texas Gulf Coast

Anchors Away

Armed with $600 million in fresh funding, Austin-based Saronic Technologies has set its sights on building a shipyard for producing remotely operated military vessels — and the futuristic shipyard could be located along the Texas Gulf Coast.

The shipyard, dubbed Port Alpha, would manufacture unstaffed midsize and large Navy ships known as “maritime drones.” Defense Newsreported that Texas — with the Gulf Coast being a prime target — is among the places under consideration for the shipyard. A timeline for construction of the shipyard hasn’t been set, and a cost estimate for the project hasn’t been revealed.

“A core principle of Saronic is that we design our vessels for autonomy from the keel up,” Saronic co-founder and CEO Dino Mavrookas, a former Navy SEAL, says in a news release. “We will take the same approach with Port Alpha, designing a shipyard from the ground up to produce at a speed and scale not seen since World War II.”

Saronic says Port Alpha would boost the U.S. shipbuilding industry, which is practically nonexistent. Consulting giant McKinsey & Co. reported in 2024 that the U.S. has gone from building about 5 percent of the world’s ocean-going ships in the 1970s to about 0.2 percent today. China, Japan, and South Korea now dominate global shipbuilding.

“The last years have seen a degradation in the capacity for the United States to build ships and to manufacture core needs of the country. I am excited to back Saronic and its focus on revitalizing shipbuilding in America, while also building products to defend those interests,” says investor and tech entrepreneur Elad Gil, who led the $600 million funding round.

The $600 million round, announced February 18, pushes the value of Saronic to $4 billion. Investors in Saronic, founded in 2022, include Gil, General Catalyst, a16z, Caffeinated Capital, and 8VC.

Last year, Saronic raised $175 million from investors, lifting the company’s value to $1 billion. In 2023, the startup collected $55 million from investors.

In the past three years, Saronic has focused on manufacturing three small remotely controlled vessels, or “maritime drones,” for the Navy: the six-foot-long Spyglass, 14-foot-long Cutlass, and 24-foot-long Corsair. Port Alpha would specialize in much bigger remotely controlled ships for the Navy. The Navy has expressed interest in assembling a modern fleet that combines staffed and unstaffed vessels.

Saronic’s nearly 420,000-square-foot factory in Austin manufactures the Spyglass, Cutlass and Corsair boats.

“The velocity and economics of warfare have fundamentally evolved, and several of our own team have witnessed firsthand how unmanned systems became true force multipliers in Afghanistan and in other theaters of conflict,” says Paul Kwan, managing director of General Catalyst.

---

This story originally was published on our sister site CultureMap Austin.

View All Listings